Fig. 1From: Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapyStudy population: patients diagnosed with hormone receptor-positive HER2-negative metastatic breast cancer from 2012 to 2018 who received everolimus exemestane in first-line, second-line, or third-lineBack to article page